JP2015518008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518008A5 JP2015518008A5 JP2015514291A JP2015514291A JP2015518008A5 JP 2015518008 A5 JP2015518008 A5 JP 2015518008A5 JP 2015514291 A JP2015514291 A JP 2015514291A JP 2015514291 A JP2015514291 A JP 2015514291A JP 2015518008 A5 JP2015518008 A5 JP 2015518008A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- aryl
- alkenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003107 substituted aryl group Chemical group 0.000 claims 23
- 239000003814 drug Substances 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 125000000547 substituted alkyl group Chemical group 0.000 claims 18
- 125000002252 acyl group Chemical group 0.000 claims 16
- -1 phosphono, phosphinyl Chemical group 0.000 claims 16
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 16
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 229940079593 drug Drugs 0.000 claims 12
- 125000005254 oxyacyl group Chemical group 0.000 claims 12
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000002062 proliferating effect Effects 0.000 claims 9
- 206010021143 Hypoxia Diseases 0.000 claims 8
- 125000004442 acylamino group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 5
- 229960001467 bortezomib Drugs 0.000 claims 5
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 5
- 229960000639 pazopanib Drugs 0.000 claims 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 125000004423 acyloxy group Chemical group 0.000 claims 4
- 125000003302 alkenyloxy group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 230000007954 hypoxia Effects 0.000 claims 4
- 230000001146 hypoxic effect Effects 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 4
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 4
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003441 thioacyl group Chemical group 0.000 claims 4
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 4
- 125000004951 trihalomethoxy group Chemical group 0.000 claims 4
- 125000004953 trihalomethyl group Chemical group 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- UGJWRPJDTDGERK-UHFFFAOYSA-N evofosfamide Chemical compound CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N+]([O-])=O UGJWRPJDTDGERK-UHFFFAOYSA-N 0.000 claims 3
- 229950009988 evofosfamide Drugs 0.000 claims 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 0 *c1c(c(Ic2c(*)c(*)c(*)c(*)c2*)c(O)[o]2)c2c(*)c(*)c1* Chemical compound *c1c(c(Ic2c(*)c(*)c(*)c(*)c2*)c(O)[o]2)c2c(*)c(*)c1* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902291 | 2012-06-01 | ||
| AU2012902291A AU2012902291A0 (en) | 2012-06-01 | Combination Therapy | |
| PCT/AU2013/000581 WO2013177633A1 (en) | 2012-06-01 | 2013-06-03 | Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518008A JP2015518008A (ja) | 2015-06-25 |
| JP2015518008A5 true JP2015518008A5 (enExample) | 2016-03-24 |
| JP6005855B2 JP6005855B2 (ja) | 2016-10-12 |
Family
ID=49672192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514291A Expired - Fee Related JP6005855B2 (ja) | 2012-06-01 | 2013-06-03 | 血管破壊薬および低酸素を標的とする薬剤を含む併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150133401A1 (enExample) |
| EP (1) | EP2854796B1 (enExample) |
| JP (1) | JP6005855B2 (enExample) |
| CN (1) | CN104703595B (enExample) |
| AU (2) | AU2013204313C1 (enExample) |
| CA (1) | CA2874778A1 (enExample) |
| IL (1) | IL235927A (enExample) |
| NZ (1) | NZ630465A (enExample) |
| WO (1) | WO2013177633A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107427487B (zh) * | 2015-03-05 | 2021-02-26 | 生态学有限公司 | 组合治疗方案 |
| EP3265091A4 (en) * | 2015-03-06 | 2018-08-01 | Beyondspring Pharmaceuticals Inc. | Method of treating a brain tumor |
| HK1249052A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗与ras突变相关的癌症的方法 |
| MX376122B (es) | 2015-07-13 | 2025-03-07 | Beyondspring Pharmaceuticals Inc | Composiciones de plinabulina. |
| SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| BR112018074990A2 (pt) | 2016-06-06 | 2019-03-12 | Beyondspring Pharmaceuticals, Inc. | composição, usos e método para reduzir neutropenia |
| US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| EP3576733A4 (en) | 2017-02-01 | 2020-11-25 | Beyondspring Pharmaceuticals, Inc. | NEUTROPENIA REDUCTION METHOD |
| ES2935729T3 (es) * | 2017-09-14 | 2023-03-09 | Lankenau Inst Medical Res | Métodos y composiciones para el tratamiento del cáncer |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| CN110680824A (zh) * | 2018-07-05 | 2020-01-14 | 深圳艾欣达伟医药科技有限公司 | 埃夫索胺的抗癌医药用途 |
| CN109675039A (zh) * | 2018-12-21 | 2019-04-26 | 中国科学院长春应用化学研究所 | 药物组合、抗肿瘤的药物和应用 |
| CN112755188B (zh) * | 2019-11-01 | 2022-03-08 | 中国科学院微生物研究所 | Shmt2抑制剂在制备抑制膀胱癌细胞生长和转移的药物中的应用 |
| EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| WO2023025291A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| JP7762796B2 (ja) | 2021-08-27 | 2025-10-30 | アセンタウィッツ ファーマシューティカルズ リミテッド | Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療 |
| CN118829436A (zh) | 2022-03-15 | 2024-10-22 | 深圳艾欣达伟医药科技有限公司 | 治疗brca突变癌症患者的方法 |
| US20250295677A1 (en) | 2022-04-15 | 2025-09-25 | Ascentawits Pharmaceuticals, Ltd. | Method for treating cancer by using th-302 alone or in combination with parp inhibitor |
| WO2023226959A1 (zh) | 2022-05-23 | 2023-11-30 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| WO2024061346A1 (zh) | 2022-09-22 | 2024-03-28 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| WO2024179467A1 (zh) | 2023-02-27 | 2024-09-06 | 深圳艾欣达伟医药科技有限公司 | 溶液、冻干制剂、冻干制剂单位包装、注射液及注射液配制方法 |
| AU2024317010A1 (en) | 2023-07-28 | 2026-02-26 | Ascentawits Pharmaceuticals, Ltd. | Treatment of p53 gene mutation or defect negative cancer and tumor patients |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340062A (en) | 1992-08-13 | 1994-08-23 | Harmon Industries, Inc. | Train control system integrating dynamic and fixed data |
| US5886025A (en) | 1997-03-06 | 1999-03-23 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
| US6162930A (en) | 1998-03-06 | 2000-12-19 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
| US6849656B1 (en) | 1999-09-17 | 2005-02-01 | Baylor University | Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents |
| AUPR283801A0 (en) | 2001-02-01 | 2001-03-01 | Australian National University, The | Chemical compounds and methods |
| WO2003070241A1 (en) | 2002-02-15 | 2003-08-28 | Rigel Pharmaceuticals, Inc. | Inhibitors of tubulin polymerization |
| US7456214B2 (en) | 2004-05-03 | 2008-11-25 | Baylor University | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
| US8278290B2 (en) | 2005-02-14 | 2012-10-02 | Biononics Limited | Tubulin polymerisation inhibitors |
| WO2006138427A2 (en) | 2005-06-14 | 2006-12-28 | Baylor University | Combretastatin analogs with tubulin binding activity |
| NZ570014A (en) * | 2006-02-03 | 2011-04-29 | Bionomics Ltd | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| US8466163B2 (en) | 2006-12-11 | 2013-06-18 | Bionomics Limited | Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization |
| KR101925436B1 (ko) * | 2008-04-10 | 2018-12-05 | 버지니아 커먼웰스 유니버시티 | 암 치료를 위한 종양 저 산소 상태의 유도 |
| US20110130367A1 (en) * | 2009-11-27 | 2011-06-02 | Bionomics Limited | Combination Therapy for Treating Proliferative Diseases |
| CA2686587C (en) * | 2009-11-27 | 2018-01-16 | Bionomics Limited | Combination therapy for treating proliferative diseases |
| WO2011063469A1 (en) * | 2009-11-27 | 2011-06-03 | Bionomics Limited | Tubulin biomarker assay |
| MX2012014428A (es) * | 2010-07-12 | 2013-03-05 | Threshold Pharmaceuticals Inc | Administracion de profarmacos activados por hipoxia y de agentes antiangiogenicos para el tratamiento de cancer. |
-
2013
- 2013-04-12 AU AU2013204313A patent/AU2013204313C1/en not_active Ceased
- 2013-06-03 CN CN201380035499.3A patent/CN104703595B/zh not_active Expired - Fee Related
- 2013-06-03 WO PCT/AU2013/000581 patent/WO2013177633A1/en not_active Ceased
- 2013-06-03 AU AU2013270425A patent/AU2013270425A1/en not_active Abandoned
- 2013-06-03 EP EP13797528.0A patent/EP2854796B1/en not_active Not-in-force
- 2013-06-03 US US14/404,782 patent/US20150133401A1/en not_active Abandoned
- 2013-06-03 NZ NZ630465A patent/NZ630465A/en not_active IP Right Cessation
- 2013-06-03 CA CA2874778A patent/CA2874778A1/en not_active Abandoned
- 2013-06-03 JP JP2015514291A patent/JP6005855B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-26 IL IL235927A patent/IL235927A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015518008A5 (enExample) | ||
| JP2018507890A5 (enExample) | ||
| JP2018522879A5 (enExample) | ||
| JP2013537229A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2015536964A5 (enExample) | ||
| JP2020504733A5 (enExample) | ||
| JP2012532136A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| TR201802093T4 (tr) | Terapötik terapilerde kullanım için akt inhibitör bileşiği ve abirateron kombinasyonu. | |
| JP2014533299A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| TR201906470T4 (tr) | İmmünomodülatörler. | |
| JP2016503414A5 (enExample) | ||
| JP2017527532A5 (enExample) | ||
| JP2010510237A5 (enExample) | ||
| JP2017510610A5 (enExample) | ||
| JP2020532547A5 (enExample) | ||
| JP2014513704A5 (enExample) | ||
| JP2016502504A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| JP2020529994A5 (enExample) | ||
| JP2006514012A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2016503797A5 (enExample) |